Vasculogenic mimicry triggers early recidivation and resistance to adjuvant therapy in esophageal cancer

To investigate the impact of vasculogenic mimicry (VM) and postoperative adjuvant therapy on the prognosis and survival of patients with esophageal squamous cell carcinoma (ESCC), as well as to assess whether VM affects the clinical benefit of postoperative adjuvant therapy. This single-center retro...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2024-09, Vol.24 (1), p.1132-10, Article 1132
Main Authors: Chen, Jue, Wang, Yu, Wu, Mengke, Yu, Keke, Liu, Junchi, Chang, Jiayu
Format: Article
Language:English
Subjects:
Adjuvant therapy
Adjuvant treatment
Adjuvants
Aged
Analysis
Antibodies
Blood-vessels
Cancer
Cancer therapies
Care and treatment
Chemoradiotherapy
Chemotherapy, Adjuvant - methods
Development and progression
Drug resistance
Drug Resistance, Neoplasm
Esophageal cancer
Esophageal carcinoma
Esophageal Neoplasms - mortality
Esophageal Neoplasms - pathology
Esophageal Neoplasms - therapy
Esophageal squamous cell carcinoma
Esophageal Squamous Cell Carcinoma - mortality
Esophageal Squamous Cell Carcinoma - pathology
Esophageal Squamous Cell Carcinoma - surgery
Esophageal Squamous Cell Carcinoma - therapy
Esophagectomy
Female
Health aspects
Humans
Lymphatic system
Male
Medical prognosis
Medical records
Medical research
Medicine, Experimental
Metastases
Metastasis
Microcirculation
Middle Aged
Mimicry
Neoplasm Recurrence, Local
Neoplasm Staging
Neovascularization, Pathologic
Patient outcomes
Patients
Postoperative adjuvant therapy
Postoperative care
Prognosis
Reagents
Relapse
Retrospective Studies
Risk factors
Squamous cell carcinoma
Surgery
Survival analysis
Tumors
Vascular mimicry
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the impact of vasculogenic mimicry (VM) and postoperative adjuvant therapy on the prognosis and survival of patients with esophageal squamous cell carcinoma (ESCC), as well as to assess whether VM affects the clinical benefit of postoperative adjuvant therapy. This single-center retrospective analysis included patients who underwent radical surgery for ESCC, which was documented in the medical record system. The presence or absence of VM in surgical specimens was determined using double staining with PAS/CD31. Stratification was applied based on adjuvant therapy and VM status. Survival curves and COX modeling were used to analyze the impact of the presence or absence of VM on the benefit of adjuvant therapy and the survival prognosis of patients. VM-positive patients were more prone to postoperative recurrence and metastasis. VM was identified as an independent risk factor for progression-free survival (PFS) (p 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-024-12903-5